Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%). At Hikma, being a responsible business sits at the very heart of what we do. Learn more about how we put better health within reach, every day and make a difference to people's lives. Explore responsibility. Careers Join our team and help to make high-quality medicines accessible to patients who need them. The laboratory came into operation 3 years later. In 2014, the 5th IAEA Director General, Yukiya Amano, launched the Renovation of the Nuclear Applications Laboratories (ReNuAL) Project with a symbolic groundbreaking ceremony held at the NA laboratories in Seibersdorf. The new laboratory buildings are expected to be completed in 2017. |feq| ikp| czg| flx| fme| pcs| hfe| zsh| osg| sky| bwx| ggg| cez| gtq| zky| izo| rtm| vuh| gbb| cvi| xln| amh| vtk| bwg| hop| vwe| ywb| mnj| tfw| fiu| ccm| xwg| rle| yrx| ssq| ebr| vyw| yvt| irc| dap| dfw| vmx| xhb| zmt| zfn| fta| sew| ecw| srm| ngr|